Sign In
Buy LIVN
$80.14
-0.91 (-1.12%)
At Close: Jul 31, 2026
LivaNova Reports Second Quarter 2020 Results
09:00am, Wednesday, 29'th Jul 2020
LivaNova PLC, a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2020.
Analysts Estimate LivaNova (LIVN) to Report a Decline in Earnings: What to Look Out for
04:33pm, Wednesday, 22'nd Jul 2020
LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Did Hedge Funds Make The Right Call On LivaNova PLC (LIVN) ?
10:38pm, Monday, 20'th Jul 2020
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filin
LivaNova Announces Commercial Launch of Perceval Plus Aortic Heart Valve in Europe
01:00pm, Thursday, 16'th Jul 2020
LivaNova PLC today announced the advanced Perceval® Plus sutureless surgical aortic heart valve is now available for commercial release in Europe.
LivaNova announced a publication in Contemporary Clinical Trials about the RECOVER study design for VNS Therapy for treatment-resistant depression.
LivaNova to Host Conference Call for Second Quarter 2020 Results
01:00pm, Monday, 29'th Jun 2020
LivaNova PLC will host a conference call to discuss its second quarter 2020 results on Wednesday, July 29, 2020 at 12 p.m. London time (7 a.m. EDT).
Hedge Funds Are Getting Bullish On LivaNova PLC (LIVN)
07:09pm, Monday, 15'th Jun 2020
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F
LivaNova Announces Pricing of Private Offering of $250 Million of 3.00% Cash Exchangeable Senior Notes Due 2025
12:30pm, Friday, 12'th Jun 2020
LivaNova PLC today announced the pricing of $250 million aggregate principal amount of 3.00% cash exchangeable senior notes due 2025.
LivaNova Announces Proposed Private Offering of $250 Million of Cash Exchangeable Senior Notes
10:55am, Thursday, 11'th Jun 2020
LivaNova PLC announced its intention to offer $250 million aggregate principal amount of cash exchangeable senior notes due 2025 in private offering.
LivaNova Announces New Senior Secured Credit Facility
10:52am, Thursday, 11'th Jun 2020
LivaNova PLC today announced its entry into a five-year $450m senior secured credit facility with funds managed by affiliates of Ares Management Corp.
Here’s Why LivaNova (LIVN) Stock is an Attractive Pick for Investors
02:09pm, Monday, 08'th Jun 2020
Diamond Hill Capital recently released its Q1 2020 Investor Letter, a copy of which you can download below. The Diamond Hill Small Cap Fund posted a return of -36.17% for the quarter, underperforming
LivaNova to Present at the Jefferies Virtual Healthcare Conference
01:00pm, Monday, 01'st Jun 2020
LivaNova PLC announced Thad Huston, CFO, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4 at 11 a.m. Eastern.
New Data on LivaNova Perceval Sutureless Aortic Valve Show Consistent Outcomes, Lower Procedure Times Compared to Sutured Valves
01:00pm, Thursday, 28'th May 2020
LivaNova PLC presented the first data from the Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement (PERSIST-AVR) clinical study.
New Study Shows Significant Positive Impact of Vagus Nerve Stimulation Therapy for Patients with Treatment-Resistant Bipolar Depression
01:00pm, Wednesday, 20'th May 2020
LivaNova PLC announced publication of a new study that showed positive impact from VNS Therapy for treatment-resistant bipolar depression.
LivaNova to Present PERSIST-AVR Findings at American Association for Thoracic Surgery 100th Annual Meeting
01:00pm, Tuesday, 19'th May 2020
LivaNova will present findings from its Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement (PERSIST-AVR) clinical study at AATS.
